01:16 , Feb 27, 2018 |  BC Extra  |  Preclinical News

Mutant p53 promotes tumor growth via exosomal miR-1246

A new study from the National Institutes of Health suggests mutant p53 promotes cancer progression by creating an immunosuppressive tumor microenvironment, in addition to its known roles inside cancer cells. p53 is one of the...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

MiR-103/107: Phase I started

AstraZeneca began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of subcutaneous AZD4076 in about 48 healthy male volunteers. The trial start triggered a $10 million milestone payment to Regulus from...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myosin regulatory light chain interacting protein (MYLIP; MIR; IDOL)

Neurology INDICATION: Alzheimer's disease (AD) Cell culture and mouse studies suggest inhibiting MYLIP could help treat AD. In a mouse neuronal cell line and primary mouse neurons incubated with β-amyloid 42 (Aβ42), MYLIP knockdown increased...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Reveal G4 Rapid HIV-1 Antibody Test regulatory update

FDA approved MedMira’s Reveal G4 Rapid HIV-1 Antibody Test to detect HIV-1 antibodies in fingerstick and venipuncture whole blood. The point-of-care test uses the company’s Rapid Vertical Flow Technology for rapid analysis of samples. MedMira...
07:00 , Jun 29, 2015 |  BioCentury  |  Emerging Company Profile

Swallowing large molecules

Researchers have been working on oral delivery of peptides and antibodies for decades with limited success. Rani Therapeutics LLC is taking a different approach, with an orally delivered, pH-activated capsule that uses sugar needles to...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Myosin regulatory light chain interacting protein (MYLIP; MIR; IDOL); liver X receptor (LXR) Nonhuman primate studies suggest combining MYLIP inhibitors with LXR agonists...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Company News

Competitive Technologies management update

Competitive Technologies Inc. (OTCQX:CTTC), Fairfield, Conn.   Business: Neurology, Supply/Service   Hired: Conrad Mir as president, CEO, interim CFO and a director, formerly CFO of Pressure BioSciences Inc. ; he succeeds Carl O'Connell, who remains...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Circulomics supply/service, diagnostic news

Circulomics received two Phase I Small Business Innovative Research (SBIR) grants totaling $800,000 over two years to develop its Ligo-miR microRNA assay technology and PicoSep single molecule analysis instrument. Circulomics' Ligo-miR technology uses PCR-free, ligation-based...
07:00 , May 3, 2012 |  BC Innovations  |  Cover Story

Heart beats fat

Researchers from The University of Texas Southwestern Medical Center have discovered that knocking down microRNA-208a in the heart leads to systemic benefits in obesity and metabolic disease, in addition to the already known effects on...